M-134, a novel HDAC6-selective inhibitor, markedly improved arthritic severity in a rodent model of rheumatoid arthritis when combined with tofacitinib.

Daekwon BaeYoungil ChoiJiyoung LeeNina HaDonghyeon SuhJiyeon BaekJinsol ParkWoo-Chan Son

Published in: Pharmacological reports : PR (2020)

M-134 and tofacitinib combination therapy is a potential option for the treatment of RA through the regulation of cytokines, chemokines, and adhesion molecules.

Keyphrases

rheumatoid arthritis
combination therapy
disease activity
interstitial lung disease
ankylosing spondylitis
ulcerative colitis
staphylococcus aureus
human health
risk assessment
escherichia coli
cell migration
histone deacetylase
cystic fibrosis